AzTrials
AzTrials

Covid19NCT04556565

MIND/COVID-19: Mental Health Impact and NeeDs Associated With COVID-19: a Comprehensive National Evaluation in Spain

An observational study of Covid19 and Mental Health Disorder, run by Jordi Alonso at 18 sites in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of the proposed project is to provide a comprehensive assessment of the mental health impact of the ongoing COVID-19 outbreak in Spain. A prospective cohort study of three groups will be conducted: (1) COVID-19 cases or close contacts recently isolated or quarantined; (2) healthcare workers; (3) adult general… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
How many people
16,000 participants
Where
18 sitesSpain
Study dates
8 May 2020to Nov 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Three separate population groups will be assessed: (1) recently isolated or quarantined COVID-19 cases and close contacts; (2) healthcare workers, including medical personnel directly and indirectly involved with patients as well as other personnel (e.g. administrative workers); (3) a representative sample of the general adult population (including those tele-working and working outside of home).

Who may be able to join

  • Recently isolated or quarantined cases and close contacts:
  • Individuals aged 18 or older; and b) laboratory confirmed or suspected COVID-19 cases or quarantined close contacts.
  • Healthcare workers:
  • health center employees currently working in the participating institutions, including medical and nursing personnel directly and indirectly involved with patients as well as all other personnel (administrative workers, logistic workers, etc.); and b) aged 18 years or older.
  • Spanish general adult population:
  • residents in Spain; b) aged 18 years or older; c) with a land-line or mobile telephone

Who cannot join

  • Recently isolated or quarantined cases and close contacts:
  • individuals too sick to participate (but they will become eligible after clinical improvement); b) unable to understand the survey language; and c) do not provide explicit consent to participate.
  • Healthcare workers:
  • individuals too sick to participate (but they will become eligible after clinical improvement); b) unable to understand the survey language; and c) do not provide explicit consent to participate.
  • Spanish general adult population:
  • unable to understand the survey language; and b) do not provide explicit consent to participate.

Trial locations and contacts

18 sites in 1 country.

18 sites in 1 country

Spain18 sites
  • Hospital Universitario Príncipe Asturias

    Alcalá de Henares

  • Hospital Universitario Torrecárdenas

    Almería

  • Agència de Salut Pública Barcelona

    Barcelona

  • Fundació Clínic per a la Recerca Biomèdica

    Barcelona

  • Hospital Universitari Vall d'Hebron

    Barcelona

  • Institut d'Investigación en Atenció Primària, IDIAP Jordi Gol

    Barcelona

  • Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

    Barcelona

  • Parc Sanitari Sant Joan de Déu

    Barcelona

  • Psmar-Imim

    Barcelona

  • Sistema de Emergencias Médicas de Cataluña

    Barcelona

  • Hospital Universitario Cruces

    Bilbao

  • Hospital El Bierzo

    León

  • Gerencia de Atención Primaria de Madrid-FIIBAP

    Madrid

  • Hospital General Universitario Gregorio Marañón

    Madrid

  • Hospital Universitario 12 Octubre

    Madrid

  • Hospital Universitario Donostia

    San Sebastián

  • Hospital Clínic Universitari

    Valencia

  • Hospital Universitario Araba-Santiago

    Vitoria-Gasteiz

Other trials in Spain

About this study

The aim of the proposed project is to provide a comprehensive assessment of the mental health impact of the ongoing COVID-19 outbreak in Spain. A prospective cohort study of three groups will be conducted: (1) COVID-19 cases or close contacts recently isolated or quarantined; (2) healthcare workers; (3) adult general population.

Recruitment through epidemiologic surveillance services, hospitals, primary care centers in 6 Spanish Autonomous Communities (groups 1 \& 2) and a random sample of individuals using telephone numbers as the sampling frames(group 3). Web-based surveys or telephone interviews at baseline and 6-month follow-up assess: current living and employment status; COVID-19 infection status; mental health (post-traumatic stress, panic, depression, anxiety, alcohol and substance use, suicidality; services use); psychological functioning; general health status and quality of life. Specific modules focus on isolation or quarantine (group 1) and care for COVID-19 patients (group 2). Short bi-weekly brief follow-up surveys among groups 1 \& 2 will provide additional assessment of main outcomes in the two months following baseline assessment.

Read the detailed description

Background

Previous research on infectious disease outbreaks found substantial mental health impact among cases placed under isolation or quarantine, among those working in the various healthcare systems managing the outbreaks, and in the general population. Mental disorders expected to rise during and after viral outbreaks include anxiety disorders, especially post-traumatic stress disorder, as well as depression, and suicidality.

Justification

The magnitude of the ongoing 2019 novel coronavirus disease (COVID-19) pandemic points to the urgent need to quantify mental health impact of the outbreak. Epidemiological research enables rapid health needs assessment to benchmark and monitor the ongoing onset and persistence of adverse mental health outcomes in the population, and to provide situational awareness, i.e., essential information to understand current and midterm mental healthcare needs, plan adequate responses, and allocate appropriate resources. The project is part of an ongoing international effort to collect cross-nationally comparable data on the mental health impact of the COVID-19 pandemic (World Mental Health Surveys).

Hypotheses:

  1. Adverse mental health outcomes, such as symptoms of depression and anxiety(1), post-traumatic stress disorder, and suicide, will increase from the onset of the COVID-19 outbreak, compared to the previous mental health status. The most pronounced increase will be in vulnerable groups, i.e., among recently isolated or quarantined individuals and healthcare workers.
  2. Working as healthcare worker, having been quarantined, having family members dead by COVID19 will be some of the substantial risk factors to develop sub-sequent high levels of adverse mental health. Also, some preoutbreak individual characteristics will be predictors of the mental and psychological health impact, such as the level of formal education or having a history of psychiatric illness.
  3. A substantial part of the participants would require mental health services and some type of psychological support. Most of the subjects reporting symptoms will not be using the already available resources.

OBJECTIVES

The primary objectives of the proposed project are to:

  1. assess the mental and psychological health impact of the COVID-19 outbreak among cases or close contacts recently isolated or quarantined, healthcare workers and the general population
  2. identify risk and protective factors for adverse mental health onset and persistence;
  3. quantify the use of available mental health resources;
  4. quantify and characterize unmet mental healthcare needs. These objectives will be achieved both at the short-term (onset and bi-weekly surveys) and the medium term (6 months).

The secondary objectives of the proposed project are to:

  1. assess the potential benefits of using available mental health resources;
  2. provide a reference point (benchmark) and evolution over time for future long-term research on COVID-19 related mental and psychological health impact in the population.

Study population and recruitment

Three separate population groups will be assessed: (1) recently isolated or quarantined COVID-19 cases and close contacts; (2) healthcare workers, including medical personnel directly and indirectly involved with patients as well as other personnel (e.g. administrative workers) and (3) a representative sample of the general adult population (including those tele-working and working outside of home).

Even though the terms quarantine and isolation are often used interchangeably, here we differentiate them following Brooks et al. According to this, Quarantine is the separation and restriction of movement of people who have potentially been exposed to a contagious disease to ascertain if they become unwell, so reducing the risk of them infecting others, and Isolation is the separation of people who have been diagnosed with a contagious disease from people who are not sick. Finally, we use the term confinement to define the situation of the population in Spain who, in order to prevent further spread of the virus, has been restricted to stay at home, and is only allowed to get out for specific tasks that need to be justified.

Calculation and justification of the sample size

General population: a fixed sample size of n= 3,500 ensures a two-sided 95%CI of 0.025 for a sample proportion of 0.20. Health professionals: up to 85,000 professionals work in the participating institutions (30,000 at primary health care centers, 55,000 at hospitals). Assuming a 15% participation rate, we expect a sample size of >10,000. COVID-19 cases: Given high numbers of (hospitalized) cases in Barcelona and Community of Madrid (the main recruitment areas) and the population coverage of the participating institutions, we expect to recruit n=2,000 cases and close contacts. Within each population subgroup, a sample of at least 2,000 individuals achieves power > 0.80, with alpha=0.05, to detect an odds ratio of 1.6 on a binary independent variable (of which 30% are in the group X=1) from a multivariable logistic regression (with R2 < 0.3 between X and remaining independent variables). An overall sample of 16,000 achieves power > 0.90 to detect an odds ratio of 1.2 under the same conditions.

Study methodology/Procedures

Adult population groups 1 (cases and close contacts) and 2 (healthcare workers) will be assessed at baseline using web-based self-report surveys (with response time ~15 minutes) including both common and specific modules (specific for groups 1 \& 2). People with unavoidable limitations to answer the webbased questionnaire will also be eligible to participate in the study. In this case, the interview will be conducted by telephone. The telephone interview will be carried out from the same center or may be outsourced, subject to the patient's consent to share his/her contact details. Additionally, upon completion of the baseline survey, group 1 (cases and close contacts) and group 2 (healthcare workers) will be invited to respond very brief bi-weekly surveys (response time 3 - 5 minutes) on a maximum of 4 occasions to prospectively assess adverse mental health and the use of available resources to counter mental health impact. General population participants will be assessed through telephone interviews. All baseline participants of the 3 adult population groups will be assessed at 6 months follow-up using web-based self-report surveys or telephone interviews similar to their baseline assessment. At follow-up, groups 1 and 2 will also receive more extensive clinical screeners that allow to accurately assess common psychiatric disorders.

Analyses

The data will be pseudo-anonymized through encrypted identifiers, separating the personal information from the rest of the study data, to guarantee privacy and ensure the anonymized treatment of the data in the analysis.

Descriptive statistics of mental health status, mental health service use, and use of available resources at baseline and 6-month follow-up, and bivariate associations of these outcomes with potential risk and protective factors are estimated, stratified by population groups.

Bi-weekly brief survey data will be analyzed using time-lagged multilevel models and network analysis to estimate the associations of short-term dynamic risk and protective factors with mental health status and use of resources.

Multivariable generalized linear models will be used to identify baseline risk and protective factors for onset and persistence/deterioration of adverse mental health outcomes at follow-up. Potential benefits of use of available resources on preventing onset or persistence of adverse mental health outcomes will be analyzed using propensity scores methods to address the lack of baseline randomization and likely imbalance between treatment groups (natural experiment research design). All analyses will adjust for time-of-survey.

Multiple imputation methods will be used to deal with missing values.

LIMITATIONS AND RISK AND CONTINGENCY PLANS

The established network of collaborators we already have in place guarantees adequate recruitment of otherwise hard-to-reach groups 1 and 2 (cases and close contacts, healthcare workers). The lack of randomized sampling of surveillance agencies and healthcare facilities may affect representativeness of findings; this limitation will be countered by statistical weighting techniques based on all information available a posteriori in centralized national case register and healthcare facility data. Response rates will be maximized by repeated invitations and reminders.

ETHICAL CONSIDERATIONS AND CONFIDENTIALITY

The study is in line with the principles established by national and international regulations, including the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brasil, Oct 2013) and the Code of Ethics. The project will start upon approval by the independent PSMAR Clinical Research Ethics Committee (PSMAR-CEIm). Recruitment in collaborating institutions will be initiated only after project approval by its corresponding ethics committee, whenever additional approval is required.

All personal data will be handled following Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016, and the national Organic Law 3/2018, of December 5. All participants will provide explicit informed consent. When participants access the link to the online questionnaire platform, the participant's information form specific for the subpopulation they belong to will appear in the first screen, which will be written in understandable language, and will describe in clear language the aims, methods, and implications of the research. At the end of the information about the study, the different points of the informed consent will be presented in the form of check options that will have to be clicked. Access to the questionnaire will only be allowed if all check options have been activated.

The answers to the different consent questions will be stored in the database, together with the other responses, and may be used as evidence that the participant did, indeed, consent. Exemption from obtaining a signed informed consent has been requested, given the observational, online data collection nature of the study and given the fact that, to be able to access the questionnaire, respondents will have to actively check all consent questions

The Qualtrics survey platform (web-based surveys; qualtrics.com) will be used for data collection in subpopulations of cases and close contacts (1) and healthcare center workers (2). This platform has three of the most important security certifications: FedRAMP, ISO 27001 and HITRUST Common Security Framework (CSF), to meet the security requirements of the most regulated industries and organizations and those of the RGPD (European General Data Protection Regulation). In addition, the platform has additional technology that allows the user to also comply with this regulation (GDPR OneTouch Data Deletion). The data collected through the platform is stored in servers located in the EU. All data stored in the EU data center is encrypted via the AES256 cypher standard. All data transmitted to the Qualtrics platform is encrypted via the industry standard protocol TLS 1.2 and higher. The only personal information that will be requested to participants in the study are contact details with the solely objective to be able to invite participants to the follow up surveys and to send reminders within the framework of the project. This personal data will be collected within the questionnaire, once the participant has given his or her consent to participate in the study. The data will be pseudo-anonymized and neither the study investigators nor the persons in charge of the analysis will have access to the personal data. Only the data manager designated for the study will be able to relate the personal data of the participants to the questionnaire responses. All data will be collected in a research file under the responsibility of the institution, will be considered confidential and will only be used by researchers for the purposes of the project. A Data Protection Officer involved in all stages of data processing has been appointed, DPO: protecciodedades@imim.es).

With regard to the Adult General Population sample (subpopulation 3), the external company IPSOS survey company (web-based surveys; ipsos.com), will be in charge of selecting the sample, inviting participants to the study and carrying out the interviews. A verbal informed consent to participate will be obtained: at the beginning of the contact call, a presentation text with information on the study will be read, and explicit consent will be asked to the participant to respond a questionnaire in two different occasions, baseline and after 6 months. This part of the call where explicit informed consent is requested will be recorded and stored. . At the end of the 6-month follow-up interview, participants will be asked again for verbal recorded consent asking permission for the company to provide contact details of the participant to the study investigators, so that investigators can recontact them for eventual subsequent follow up assessments of the study. IPSOS will ensure that personal data of the participants will be treated with the maximum confidentiality measures according to the current regulations in force (Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016, and the national Organic Law 3/2018, of December 5), and that personal data will be exclusively used within the framework of this study. IPSOS data protection policy is detailed in the following link: https://www.ipsos.com/sites/default/files/201804/Global_Data_Protection_and_Privacy_Policy.pdf.

A specific survey platform developed by IPSOS will be used in this group. IPSOS complies with all relevant regulations for the industry, including the new EU directive: GDPR, but also with the ethical, privacy and anti-spam precepts recommended by European Society for Opinion and Marketing Research (ESOMAR). The extensive privacy policy is displayed during the registration process and must be accepted by all the panelists. To this end, Ipsos applies strict data protection and security protocols for both client and respondent data. Physical security measures include strict control of access to data centers, firewalls, antivirus procedures, data retention/destruction policies, or disaster recovery plans.

Given the observational approach of the study, without therapeutic intervention, it is considered that it will pose minimum risk to the respondents. Participants with psychological distress will be provided with a list of effective care resources at the end of the questionnaire, including coordinates to nearby emergency care in case of suicidal symptoms.

Keywords
COVID-19 outbreak, Health workers, Mental Health, Suicidal thoughts and behaviours, Depression, Anxiety, Post-Traumatic Stress Disorder, General Population, Close contacts, Lockdown
Medical subject headings
COVID-19, Mental Disorders, Psychological Well-Being, Suicidal Ideation, Behavior, Depression, Anxiety Disorders, Stress Disorders, Post-Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT04556565
Study groupRoleWhat they receive
General populationA representative sample of the general adult population (including those tele-working and working outside of home)
Cases and contactsRecently isolated or quarantined COVID-19 cases and close contacts
Healthcare workersHealthcare workers, including medical personnel directly and indirectly involved with patients as well as other personnel (e.g. administrative workers)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-traumatic stress disorder

    It will be assessed with the 4-item version of the PTSD checklist for DSM-5 (PCL-5), which evaluates the presence and severity of 4 DSM-5 Criteria symptoms of PTSD over the past month (0 = not at all to 4 = extremely) and has been shown to generate diagnoses that closely parallel those of the full PCL-5 (AUC>0.9), making it well-suited for screening. The Spanish version is available.

    Measured: 6 months

  2. Depression

    It will be evaluated with the Patient Health Questionnaire 8-item version (PHQ-8) with a 2-week recall period. Items have four response categories on frequency of the symptom that can be summed up to obtain a severity score, with cut-points of 5, 10, and 15 representing mild, moderate, and severe levels of depression, respectively, showing good diagnostic accuracy for depressive disorder (AUC>0.90) and high reliability (>0.8).

    Measured: 6 months

  3. Generalized Anxiety Disorder

    It will be screened with the seven-item Generalized Anxiety Disorder scale (GAD-7). Cut-points of 5, 10, and 15 represent mild, moderate, and severe levels of anxiety, respectively, with AUC>0.8 for the detection of anxiety. The Spanish versions of the PHQ and GAD-7 have been developed (https://www.phqscreeners.com).

    Measured: 6 months

  4. Suicidal thoughts and behaviors

    It will be evaluated with a modified version of the Columbia Suicide Severity Rating Scale, including passive suicidal ideation ("wish you were dead or would go to sleep and never wake up"), active suicidal ideation ("have thoughts of killing yourself"), suicide plans ("think about how you might kill yourself [e.g., taking pills, shooting yourself] or work out a plan of how to kill yourself"), and suicide attempt ("make a suicide attempt [i.e., purposefully hurt yourself with at least some intent to die]).It has been translated into Spanish showing good discrimination ability for suicidal behavior.

    Measured: 6 months

Secondary outcomes (5)
  1. Alcohol and drug use problems

    It will be evaluated with the CAGE questionnaire, that consists of 4 items focusing on Cutting down, Annoyance by criticism, Guilty feeling, and Eye-openers and have proved useful in helping to make a diagnosis of alcoholism.Item responses on the CAGE questions are scored 0 for "no" and 1 for "yes" answers, with a higher score being an indication of alcohol problems. A total score of two or greater is considered clinically significant. The questionnaire has been adapted into Spanish.

    Measured: 6 months

  2. Panic attacks

    It will be assessed with item taken and adapted from the CIDI Screening Scales("Panic or anxiety attacks are sudden, strong feelings of fear or anxiety that reach their peak within a few minutes and are usually accompanied by physical reactions like racing heart, sweating, shortness of breath, feeling faint, or feeling sick to your stomach. People who have panic attacks sometimes feel like they might lose control, go crazy, or suddenly die. With this definition in mind, about how many panic attacks did you have since the onset of COVID-19 outbreak?")

    Measured: 6 months

  3. Health-related Quality of Life

    It will be assessed with the 5-level version of the EQ-5D-5L, for which a Spanish version is available showing good validity.

    Measured: 6 months

  4. Overall Perceived Health

    It will be evaluated with a single item assessing general health, ''In general, how would you rate your health'' with response options of ''excellent, very good, good, fair, or poor''), which has shown to have a strong association with negative health outcomes, including mortality [10.1111/j.1525-1497.2005.0291.x]. The Spanish version of the item has provided similar results .

    Measured: 6 months

  5. Role limitation

    It will be assessed using an adapted version of the Sheehan Disability Scale that assessed impairment separately in each of four role domains: home management/chores, work roles, close personal relationships, and social life.

    Measured: 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Sep 2020
  2. Study start8 May 2020
  3. Primary completion7 Nov 2021
  4. Study completionNov 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
16,000 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04556565
Sponsor's protocol ID
2020/9203/I
Status last verified
Mar 2022
First submitted
10 Sep 2020
Last updated
17 Mar 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Petri-Romao P, Stoffers-Winterling J, Doerschner C, Jurgeit J, Godde P, Hecker I, Melchior M, Czepiel D, Witteveen A, van der Ven E, Sijbrandij M, Mediavilla R, Ayuso-Mateos JL, Smith P, Lorant V, Monistrol Mula A, Haro Abad JM, Gemes K, Mittendorder-Rutz E, Monzio Compagnoni M, Lora A, Caggiu G, Conflitti C, Kalisch R, Lieb K. Co-RESPOND: a federated network of cohorts on mental health and adversity during the COVID-19 pandemic. Challenges, solutions and recommendations for retrospective data harmonization. Eur J Psychotraumatol. 2025 Dec;16(1):2517920. doi: 10.1080/20008066.2025.2517920. Epub 2025 Aug 12.

    PubMed 40791144
  • Alayo I, Pujol O, Alonso J, Ferrer M, Amigo F, Portillo-Van Diest A, Aragones E, Aragon Pena A, Asunsolo Del Barco A, Campos M, Espuga M, Gonzalez-Pinto A, Haro JM, Lopez-Fresnena N, Martinez de Salazar AD, Molina JD, Orti-Lucas RM, Parellada M, Pelayo-Teran JM, Forjaz MJ, Perez-Zapata A, Pijoan JI, Plana N, Polentinos-Castro E, Puig MT, Rius C, Sanz F, Serra C, Urreta-Barallobre I, Bruffaerts R, Vieta E, Perez-Sola V, Mortier P, Vilagut G; MINDCOVID Working group. Identifying most important predictors for suicidal thoughts and behaviours among healthcare workers active during the Spain COVID-19 pandemic: a machine-learning approach. Epidemiol Psychiatr Sci. 2025 May 8;34:e28. doi: 10.1017/S2045796025000198.

    PubMed 40340775
  • Alonso J, Vilagut G, Alayo I, Ferrer M, Amigo F, Aragon-Pena A, Aragones E, Campos M, Del Cura-Gonzalez I, Urreta I, Espuga M, Gonzalez Pinto A, Haro JM, Lopez Fresnena N, Martinez de Salazar A, Molina JD, Orti Lucas RM, Parellada M, Pelayo-Teran JM, Perez Zapata A, Pijoan JI, Plana N, Puig MT, Rius C, Rodriguez-Blazquez C, Sanz F, Serra C, Kessler RC, Bruffaerts R, Vieta E, Perez-Sola V, Mortier P; MINDCOVID Working group. Mental impact of Covid-19 among Spanish healthcare workers. A large longitudinal survey. Epidemiol Psychiatr Sci. 2022 Apr 29;31:e28. doi: 10.1017/S2045796022000130.

    PubMed 35485802
  • Mortier P, Vilagut G, Ferrer M, Alayo I, Bruffaerts R, Cristobal-Narvaez P, Del Cura-Gonzalez I, Domenech-Abella J, Felez-Nobrega M, Olaya B, Pijoan JI, Vieta E, Perez-Sola V, Kessler RC, Haro JM, Alonso J; MINDCOVID Working group; MINDCOVID Working group. Thirty-day suicidal thoughts and behaviours in the Spanish adult general population during the first wave of the Spain COVID-19 pandemic. Epidemiol Psychiatr Sci. 2021 Feb 17;30:e19. doi: 10.1017/S2045796021000093.

    PubMed 34187614

Questions about this trial

What is this clinical trial studying?

An observational study of Covid19 and Mental Health Disorder, run by Jordi Alonso at 18 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 18 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-traumatic stress disorder (time frame: 6 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04556565, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in